Zero Out-of-Pocket Clinical Study on Low-Dose Heavy Ion Therapy for BPH Launched

Zero Out-of-Pocket Clinical Study on Low-Dose Heavy Ion Therapy for BPH Launched

Gansu Wuwei Cancer Hospital, as the first clinical application hospital for China's homegrown heavy ion system and the only hospital in the world operating two heavy ion systems, has treated over 2,800 patients across more than 50 disease types—including lung cancer, pancreatic cancer, and liver cancer—over five years of clinical practice. Its clinical efficacy and patient survival rates have reached internationally advanced standards. The hospital has developed nine globally leading carbon‑ion therapy technologies: simultaneous clinical application of two heavy ion systems; extensive clinical experience with single‑fraction, one‑day regimens; precision radiotherapy under ventilator‑managed or high‑frequency oscillatory respiratory gating; pioneering bladder‑cancer heavy ion therapy with precise bladder‑capacity management; unique organ‑tumor spacer implantation for single‑session precision radiotherapy; successful heavy ion therapy for cardiac tumors; an original heavy ion therapy model integrated with whole‑life physical and mental health management; the original "dual Bragg‑lattice" radiotherapy technique; and multimodal image‑guided adaptive radiotherapy enabling dynamic precision throughout treatment.

With an aging population, the incidence of benign prostatic hyperplasia (BPH) among middle‑aged and elderly men continues to rise, making it one of the most common conditions affecting male quality of life. To further support the high‑quality development of China's heavy ion therapy, and building on previous work, the hospital is deepening clinical application research and fully advancing iterative upgrades of heavy ion therapy technology.

Currently, the Department of Urology and the Third Department of Radiotherapy at the Heavy Ion Center of Gansu Provincial Wuwei Tumor Hospital are conducting a clinical study titled "Efficacy and Safety of Low‑Dose Radiotherapy for Patients with Benign Prostatic Hyperplasia." This project aims to improve clinical symptoms and quality of life for BPH patients, establish clinical treatment standards for China's heavy ion system in treating BPH aligned with international benchmarks, and pursue better patient outcomes. The study has passed scientific review by the Clinical Trial Research Committee and approval by the Medical Ethics Committee, and is now openly recruiting participants.

Selection Criteria

• Aged between 60 and 85 years;
• Presence of moderate to severe lower urinary tract symptoms, defined as an IPSS score ≥ 8, and confirmed as benign prostatic hyperplasia (BPH) by prostate ultrasound;
• Poor symptom improvement after at least 3 months of standard medical therapy, inability to tolerate adverse drug reactions, refusal to undergo surgical treatment, or inability to tolerate surgery due to underlying cardiopulmonary, cerebrovascular, or other comorbidities;
• Generally good performance status, without organ dysfunction, and able to tolerate the proposed treatment;
• Willing to participate voluntarily in the study and able to comply with treatment and follow-up requirements.

Note: The above criteria are primary eligibility standards. Final determination of enrollment will be made by the investigator in accordance with the trial protocol.

Patient Rights

1. The hospital will provide research funding to the expert team and cover the patient's heavy ion therapy costs.
2. A multidisciplinary expert team (MDT), including urology and radiation oncology specialists, will develop a personalized treatment plan.
3. After treatment, we will closely follow up with you and provide subsequent treatment recommendations.

Contact Information

Director Tang Juntian (Urology Department) +86 13639352510

Director Chen Weizuo (Third Radiotherapy Department) +86 13519351968

Gansu Wuwei Cancer Hospital (Wuwei Institute of Medical Sciences)

(Gan) Medical Advertisement [2025] No. 11-14-387